logo-loader

ANGLE researchers copper bottom ovarian cancer results

Published: 03:04 28 Sep 2015 EDT

cancer-cells
Parsortix is effective in detecting cancer cells.

Researchers in Austria have published more “highly encouraging” results based on their work with med-tech firm ANGLE’s (LON:AGL) Parsortix device, which captures cancer cells found in the bloodstream.

Scientists at the Medical University of Vienna, building on their previous work, have determined the system is very good at detecting and identifying ovarian cancer cells.

Using the jargon, Parsortix has 78-80% ‘sensitivity’ and 100% ‘specificity’.

By contrast, the conventional process, immune-fluorescent staining, is effective in only 25% of cases.

A larger RNA panel of markers used on a subset of patients yielded even higher sensitivity whilst retaining 100% specificity, ANGLE said.

A total of 65 patients were in the Parsortix study group.

The new information forms part of a poster presentation at European Cancer Congress European Society for Medical Oncology, taking place now.

ANGLE said the work by the researchers “further substantiates the value of the Parsortix system and its applicability in detecting ovarian cancer”. 

It is collaborating with the Medical University of Vienna and other leading cancer centres to demonstrate through clinical studies the ability of Parsortix to grade, or triage, patients with abnormal pelvic mass.

Principal investigator Dr Eva Obermayr said: "The Parsortix technology clearly outperforms conventional immune-fluorescent staining. 

“The use of qPCR with the Parsortix system is both highly sensitive and specific and offers the potential for a liquid biopsy (simple blood test) to diagnose ovarian cancer. 

“This would greatly improve the standard of the care that can be offered to women with this condition."

The company estimates sales of its device for use in ovarian cancer could eventually be £300mln a year in Europe and the US.

ANGLE chief executive Andrew Newland added: "Detection of ovarian cancer is ANGLE's first clinical application for our Parsortix system.  The continued strong results from Medical University of Vienna are impressive."

ANGLE PLC present at the Proactive One2One Investor Conference - January 11th

In a comprehensive presentation at the Proactive One2One Investor Conference, ANGLE PLC (AIM:AGL, OTCQX:ANPCY) CEO, Andrew Newland, and CFO, Ian Griffiths, detailed the company's innovative approach to cancer diagnosis and treatment. Newland emphasised ANGLE's breakthrough technology, the...

on 01/17/2024